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Summary
Rituximab is a human-mouse chimeric monoclonal antibody with specifity for the CD20 antigen expressed on B-lineage cells.
We are reporting a 17-year old boy diagnosed with diffuse large B cell lymphoma, CD20(+). He was treated by standard chemotherapy and 
megachemotherapy with ASCT. The boy relapsed in the mediastinum and lungs one year after the treatment was completed. He underwent 
secondary treatment: surgical procedure, chemotherapy and immunotherapy with rituximab, second ASCT and again immunotherapy
in the post-transplantation period. No severe complications during the treatment with rituximab were observed except for leukopenia and 
central venous catheter infection. 
The CT scans performed one year after the therapy was completed showed regression of changes previously observed.
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Immunochemioterapia z zastosowaniem Rituximabu po przeszczepie 
autologicznym (ASCT) u 17-letniego pacjenta z rozpoznaniem ch³o-
niaka - opis przypadku
Streszczenie
Rituximab (Mabthera) jest ludzko-mysim przeciwcia³em monoklonalnym skierowanym wybiórczo przeciwko antygenowi b³onowemu CD20 
limfocytów B. Potwierdzona jest jego skutecznoœæ w leczeniu agresywnych ch³oniaków nieziarniczych u  doros³ych razem z konwencjonaln¹ 
chemioterapi¹ oraz w po³¹czeniu z megachemioterapi¹ i autoHSCT, równie¿ jako terapia podtrzymuj¹ca remisjê.
Przedstawiamy przypadek 17-letniego ch³opca ze wznow¹ ch³oniaka olbrzymiokomórkowego œródpiersia rozpoznan¹ rok po zakoñczeniu 
leczenia konwencjonaln¹ chemioterapi¹ i megachemioterapi¹ z auto PBSCT. Wznowê ch³oniaka stwierdzono w œródpiersiu i p³ucach.
Po operacyjnym usuniêciu guza œródpiersia i mnogich przerzutów w p³ucach przeprowadzono chemioterapiê (IVAC) z immunoterapi¹ 
(Rituximab), planuj¹c kolejn¹ megachemioterapiê z autoPBSCT. Po przeprowadzeniu megachemioterapii i auto PBSCT zdecydowano siê
2na immunoterapiê Mabthera (4 cykle co 4 tygodnie, dawka jednorazowa 375mg/m ). Przebieg immunoterapi bez powik³añ, z odchyleñ
w badaniach dodatkowych stwierdzaliœmy jedynie leukopeniê, dwukrotnie bêd¹c¹ przyczyn¹ wyd³u¿enia odstêpu miêdzy kolejnymi dawkami 
leku. 
Aktualnie ch³opiec jest rok po zakoñczeniu immunoterapii, w remisji choroby zasadniczej.
Key words: rituximab, przeszczepienie komórek macierzystych, ch³oniak B-komórkowy.
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Introduction
Rituximab (MabThera) is a human-mouse chimeric 
monoclonal antibody with specifity for the CD20 antigen 
expressed on B-lineage cells [1,2]. Its mechanism of action 
differs from other antineoplastic agents. CD20 antigen is 
expressed on more than 95% of B-cell NHL, but is not 
expressed on stem cells or plasma cells. Cell lines not 
expressing the CD20 antigen are unaffected by rituximab. 
The antibody destroys CD20-expressing cells mainly by 
cytotoxicity: complement-dependent cytotoxicity, antibody-
dependent cell-mediated cytotoxicity and induction of apo-
ptosis [1]. Clinical trials in adults treated for CD20+ NHL 
demonstrated the efficacy and safety of rituximab, both as a 
single-agent and in combination with chemotherapy [3,4,5].
Case report
We report a 17-year-old boy diagnosed with diffuse large 
B cell lymphoma localised in the mediastinum. At the time
of diagnosis a large mediastinal mass and superior caval 
vein syndrome were observed. Immunophenotype of mali-
gnant cells was: CD20 (+), CD3 (-), CD30 (+), ALK (-), The boy relapsed in the mediastinum and lungs one year 
HLADR (+), CD43 (-), CK (-). CT scans showed a large me- after completion of primary treatment. Immunophenotype 
diastinal mass and enlargement of cervical nodes (Figure of malignant cells at the relapse was the same as that
1). The first line chemotherapy was given according to the at the first diagnosis: CD20 (+), CD3 (-), CD30 (+), ALK (-), 
B-NHL-LBM 89 protocol, therapeutic group C. After comple- HLADR (+), CD43 (-), CK (-). CT scans showed a large me-
tion of standard chemotherapy and achievement of com- diastinal mass with multiple pulmonary metastases (Figu-
plete remission, high-dose chemotherapy was given re 3). Treatment of the relapse was started. The first surgical 
(BEAM) followed by autologous stem cells transplantation. procedure  extirpation of the anterior mediastinal tumour 
CT scans confirmed regression of changes previously and pulmonary metastases was performed to reduce the tu-
observed (Figure 2). mour mass. Only partial resection was possible. Afterwards 
Figure 1. CT scans at the diagnosis with large mediastinal mass.
Figure 2. Complete remission.
Figure 3. Relapse. CT scans show large mediastinal mass with multiple 
pulmonary metastases.
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chemotherapy (IVAC) with immunotherapy (rituximab) was ges seen on previous CT scans (Figure 4). During the treat-
started (four cycles every four weeks with a single dose ment with rituximab no severe complications were obser-
2of 375 mg/m ), followed by high  dose chemotherapy (Treo- ved. The consecutive dose of rituximab was delayed due to 
sulfan + Fludara) with second autologous stem cells trans- neutropenia. After the second rituximab course central 
plantation. Cells used for the second transplantation were venous catheter had to be removed because of its infection. 
harvested during the first line therapy. Immunotherapy with The patient completed the treatment and currently is 
rituximab was continued after the recovery of hemato- being followed for 12 months. Last CT scans showed 
poesis. From week 8, following ASCT, four doses of rituxi- regression of changes previously observed (Figure 5).
2mab (375 mg/m ) every 4 – 8 weeks were given. CT scans 
performed before the second transplantation showed par- Discussion
tial regression of mediastinal and pleuropulmonary chan-
Myeloablative chemotherapy combined with autologous 
stem cell transplantation (ASCT) is an effective treatment
for aggressive non-Hodgkin’s lymphoma (NHL). However 
the rate of relapse following transplantation remains a clini-
cal problem despite advances in therapy [6,7]. Pan et al. [8] 
reports that rituximab is an effective and well tolerated treat-
ment for aggressive NHL relapsing after or refractory to auto-
logous stem cell transplantation. Bucstein et.al. [9] show 
good response to rituximab in patients with relapsed follicu-
lar or mantle cell lymphoma who previously had high-dose 
chemotherapy followed by ASCT. In their study, patients re-
ceived rituximab before stem cell collection as in vivo pur-
ging in addition to eight maintenance infusions of rituximab 
after ASCT. Relapses after HSCT are due either to persisten-
ce of residual tumour cells after high-dose chemotherapy
or to contamination of the stem cell product. Many studies 
have confirmed that in vivo purging using rituximab can 
reduce the rate of relapses following ASCT [9,10,11].
The efficacy and tolerability of rituximab have been con-
firmed in many studies, and relapsed patients in the post-
transplant period can safely be retreated with rituximab 
[3,4,5]. In our case no severe complications were observed 
during the postransplantation treatment with rituximab 
except for leukopenia without severe infections.
Rituximab can be effective in a variety of settings. It can be 
used alone or in combination with chemotherapy in the first 
line treatment of CD20+ NHL, before stem cell collection
as in vivo purging, or as a maintenance treatment following 
ASCT. It also appears to be an efficient and safe form of the-
rapy in B-lymhoproliferative post-transplant disorders, e.g. 
severe complications following organ and bone marrow 
transplantation [12]. 
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